Spero Therapeutics, Inc. (SPRO) is a Healthcare stock trading at $1.23 (as of 2026-08-21), with a market capitalization of $70.93M and a trailing P/E of 9.6. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Spero Therapeutics is a clinical-stage biopharmaceutical company developing treatments for multi-drug resistant bacterial infections and rare diseases, and it generates small amounts of collaboration revenue while advancing candidates such as tebipenem pivoxil HBr, SPR206, and SPR720.
Near-term revenue is largely collaboration-driven (current and grant revenue are shown as 0.0), while operating results are deeply negative, so the profit model depends on future clinical progress that can lead to larger partnerships and commercialization rather than on a current sales base.
| Collab | $0.0B |
| Current | $0.0B |
| Grant | $0.0B |
Business quality (Weak): Useful clinical and revenue-type disclosures are provided, but the latest-quarter revenue is effectively near zero, and segment detail is limited to revenue categories rather than product-specific streams.
Valuation: At 8× earnings, SPRO trades 50% below the Pharmaceutical Products average (17×). Note: one-time items can distort reported P/E.
| Price | $1.23 |
| Market Cap | $70.93M |
| P/E Ratio | 9.6 |
| EV / EBITDA | 3.3 |
| Price / Book | 1.60 |
| Price / Sales | 1.51 |
| Revenue (TTM) | $66.80M |
| Net Margin | 12.8% |
| Revenue Growth (YoY) | -100.0% |
| EPS Growth (YoY) | 433.3% |
| Altman Z-Score | -2.58 (distress) |
| Stock P/E | 9.6 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| vs Sector | -55.7% |
| vs Industry | -43.3% |
| Top Institutional Holder | GSK plc ($21.51M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Esther Rajavelu |
| Employees | 32 |
| Country | US |
| IPO Date | 2017-11-02 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.